Dr. Martens Plc (DE:3U2)
FRANKFURT:3U2
Holding DE:3U2?
Track your performance easily

Dr. Martens Plc (3U2) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

3U2 Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Dr.
Martens Plc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

3U2 Stock 12 Month Forecast

There Are No Analyst Ratings for DE:3U2 In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

3U2 Financial Forecast

3U2 Earnings Forecast

Next quarter’s earnings estimate for 3U2 is -€0.06 with a range of -€0.06 to -€0.06. The previous quarter’s EPS was €0.06. 3U2 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.71% of the time in the same period. In the last calendar year 3U2 has Underperformed its overall industry.
Next quarter’s earnings estimate for 3U2 is -€0.06 with a range of -€0.06 to -€0.06. The previous quarter’s EPS was €0.06. 3U2 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.71% of the time in the same period. In the last calendar year 3U2 has Underperformed its overall industry.

3U2 Sales Forecast

Next quarter’s sales forecast for 3U2 is €371.00M with a range of €371.00M to €371.00M. The previous quarter’s sales results were €570.40M. 3U2 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.40% of the time in the same period. In the last calendar year 3U2 has Underperformed its overall industry.
Next quarter’s sales forecast for 3U2 is €371.00M with a range of €371.00M to €371.00M. The previous quarter’s sales results were €570.40M. 3U2 beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 49.40% of the time in the same period. In the last calendar year 3U2 has Underperformed its overall industry.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays
€0.95€1.01
Hold
50.98%
Upside
Reiterated
06/20/24
RBC Capital
€0.76€0.94
Hold
39.70%
Upside
Reiterated
06/05/24
Goldman Sachs
€1.02€0.82
Sell
22.24%
Upside
Reiterated
05/31/24
Dr. Martens Plc (DOCS.L): In-line FY24; FY25 year of transition with cost saving action; remain 2024 | 7:08AM BST FY24 sales slightly below expectations, but EBITDA in line and FY25 sales outlook 2H weighted. This morning (May 30), Dr. Martens released FY24 earnings (post a Q4 trading update on April 16th) and reported adjusted EBITDA of £197.5mn (in line with company guidance and consensus) with FY24 EBITDA margins decreasing 200bps yoy to 13.9%. In addition, Dr. Martens commented on current trading and confirmed performance is in line with their expectations. They now expect revenue decline of -20% cFX in 1H25 driven by wholesale, which is expected to decline by a third in the period driven by weak order book and excess inventory in the channel.
Deutsche Bank
<€0.01€0.88
Hold
30.97%
Upside
Reiterated
05/31/24
Dr. Martens Plc (DOCS:LN) PT Raised to GBP0.75 at Deutsche BankDeutsche Bank analyst Alison Lygo raised the price target on Dr. Martens Plc (DOCS:LN) to GBP0.75 (from GBP0.65) while maintaining a Hold rating.
HSBC
€1.13€0.83
Hold
24.33%
Upside
Reiterated
04/26/24
Dr. Martens Plc (DOCS:LN) PT Lowered to GBP0.70 at HSBCHSBC analyst Doriana Russo lowered the price target on Dr. Martens Plc (DOCS:LN) to GBP0.70 (from GBP0.95) while maintaining a Hold rating.
Morgan Stanley
€0.88
Hold
30.97%
Upside
Reiterated
04/16/24
We think investors will be surprised by the extent of the downgrade, despite the series of guide downs the company has given over the past 18 months. We expect consensus to significantly de-risk 2025 forecasts on the back of the news, even with the company pointing to their guidance as a "worse case scenario". We cut our numbers in line with their worse case scenario guidance.

Best Analysts Covering Dr. Martens Plc

Which Analyst Should I Follow If I Want to Buy DE:3U2 and Sell After:
1 Month
xxx
Success Rate
2/5 ratings generated profit
40%
Average Return
-1.16%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 40.00% of your transactions generating a profit, with an average return of -1.16% per trade.
3 Months
xxx
Success Rate
2/5 ratings generated profit
40%
Average Return
-6.76%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of -6.76% per trade.
1 Year
Louise SinglehurstGoldman Sachs
Success Rate
3/5 ratings generated profit
60%
Average Return
-8.04%
reiterated a sell rating 4 months ago
Copying Louise Singlehurst's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of -8.04% per trade.
2 Years
xxx
Success Rate
3/5 ratings generated profit
60%
Average Return
-13.72%
reiterated a xxx
rating 4 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 60.00% of your transactions generating a profit, with an average return of -13.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3U2 Analyst Recommendation Trends

Rating
Jan 24
Mar 24
Apr 24
May 24
Jun 24
Strong Buy
0
0
0
0
0
Buy
0
0
0
0
0
Hold
11
9
9
7
8
Sell
0
1
2
3
2
Strong Sell
0
0
0
0
0
total
11
10
11
10
10
In the current month, 3U2 has received 0 Buy Ratings, 8 Hold Ratings, and 2 Sell Ratings. 3U2 average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Consumer Cyclical Sector
Find stocks in the Consumer Cyclical sector that are highly recommended by Top Performing Analysts.

3U2 Stock Forecast FAQ

What is DE:3U2’s average 12-month price target, according to analysts?
Currently, no data Available
What is DE:3U2’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for DE:3U2, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is Dr. Martens Plc a Buy, Sell or Hold?
      Currently, no data Available
      What is Dr. Martens Plc’s share price target?
      Currently, no data Available
      What do analysts say about Dr. Martens Plc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of Dr. Martens Plc?
      To buy shares of DE:3U2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis